Conclusion: We reported four novel pathogenic FGD1 variations in AAS patients and confirmed the efficacy and safety of growth hormone treatment in FGD1-related AAS patients with growth hormone deficiency. The gene discussed is GH1; the disease is Aarskog-Scott syndrome, X-linked.